Last edition
News about
Indoco Remedies Clears Malta Medicines Authority Audit
Indoco Remedies receives EU GMP certification from the Malta Medicines Authority, validating compliance with European Good Manufacturing Practice (GMP) standards.
Chugai Pharmaceutical Files Japan Approval for Gazyva in Idiopathic Nephrotic Syndrome
Chugai Pharmaceutical files a regulatory application in Japan for Gazyva to treat Idiopathic Nephrotic Syndrome (INS), based on phase 3 INShore study results.
US FDA Approves INQOVI Plus Venetoclax for AML
The US Food and Drug Administration (FDA) approves INQOVI with venetoclax as the first all-oral combination treatment for acute myeloid leukemia patients ineligible for intensive chemotherapy, supported by positive ASCERTAIN-V trial data.
Rockwell Medical Secures 3-Year Product Purchase Agreement with Heritage Dialysis
Rockwell Medical signs a 3-year supply agreement with Heritage Dialysis to provide hemodialysis products including PureCart, RenalPure, and SteriLyte solutions.
TDB-DST Backs Helix Cell Therapeutics for CAR-T Therapy against Multiple Myeloma
Technology Development Board (TDB) supports Helix Cell Therapeutics and Biocell Innovations in developing dual-targeting CAR-T cell therapy for multiple myeloma under an Indo-Singapore collaboration.
Zydus Worldwide DMCC to Acquire Assertio Holdings
Zydus Worldwide DMCC to acquire Assertio Holdings in a USD 166.4 million all-cash deal at USD 23.50 per share.
Lupin Secures FDA Approval for Famotidine Injection USP
Lupin has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Famotidine injection USP, 20 mg/2 mL (10 mg/mL), single-dose vials.
Boehringer Ingelheim Licenses Inflammation Antibody Program from Immunitas Therapeutics
Boehringer Ingelheim licenses a first-in-class antibody program from Immunitas Therapeutics to develop targeted therapies for chronic inflammatory diseases and expand its immunology pipeline.
Eli Lilly and Company Launches Lormalzi for Early-Stage Alzheimer's Treatment in India
Eli Lilly and Company India has launched Lormalzi, a once-monthly amyloid-targeting therapy approved for early-stage Alzheimer’s disease, marking a significant advancement in evidence-based treatment options for cognitive decline in India.
AstraZeneca Pharma India has launched K+ Connect, a nationwide initiative bringing together multidisciplinary experts from 33 healthcare centres to strengthen long-term hyperkalaemia management in patients with heart failure and chronic kidney disease.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy